With FDA nod for HAE drug Andembry, CSL set to compete with Takeda's Takhzyro
With the FDA's approval of hereditary angioedema preventative treatment Andembry, CSL is ready to take on Takeda’s blockbuster Takhzyro and BioCryst Pharmaceuticals’ fast-rising Orladeyo in a competitive market to treat patients with the rare genetic condition.
